45 participants
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-12
- Start Date:
- 2025-02-27
- Completion:
- 2027-05-30
Conditions
- Premalignant Lesion
Interventions
- DRUG
No Results Yet